当前位置:首页 - 行情中心 - 明德生物(002932) - 财务分析 - 现金流量表

明德生物

(002932)

  

流通市值:28.25亿  总市值:42.09亿
流通股本:1.56亿   总股本:2.33亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金411,843,926.61257,863,634.62146,015,819.62831,401,292.6
  收到的税费返还471.49471.49471.494,336,172.78
  收到其他与经营活动有关的现金62,591,836.7248,165,475.858,340,204.53110,876,129.64
  经营活动现金流入小计474,436,234.82306,029,581.96154,356,495.64946,613,595.02
  购买商品、接受劳务支付的现金323,086,816.4228,018,762.0491,446,330.04659,657,555.1
  支付给职工以及为职工支付的现金128,645,133.6895,000,199.5249,538,464.65234,434,922.42
  支付的各项税费13,663,935.7210,310,459.614,535,519.988,788,821.9
  支付其他与经营活动有关的现金97,442,133.0160,356,171.1139,360,669.3128,778,735.17
  经营活动现金流出小计562,838,018.81393,685,592.28184,880,983.971,031,660,034.59
  经营活动产生的现金流量净额-88,401,783.99-87,656,010.32-30,524,488.33-85,046,439.57
二、投资活动产生的现金流量:
  收回投资收到的现金744,165,000480,000,00030,000,000753,697,671.23
  取得投资收益收到的现金46,586,931.430,273,181.41,992,423.7817,824,483.44
  处置固定资产、无形资产和其他长期资产收回的现金净额3,663,494.1129,030.970778,693.82
  收到的其他与投资活动有关的现金591,250---
  投资活动现金流入小计795,006,675.5510,402,212.3731,992,423.78772,300,848.49
  购建固定资产、无形资产和其他长期资产支付的现金63,879,706.854,622,742.2344,515,255.12184,765,977.49
  投资支付的现金556,946,438.36233,946,438.3682,500,000725,659,506.84
  投资活动现金流出小计620,826,145.16288,569,180.59127,015,255.12910,425,484.33
  投资活动产生的现金流量净额174,180,530.34221,833,031.78-95,022,831.34-138,124,635.84
三、筹资活动产生的现金流量:
  取得借款收到的现金---3,000,000
  收到其他与筹资活动有关的现金---18,876,745.99
  筹资活动现金流入平衡项目---0
  筹资活动现金流入小计---21,876,745.99
  偿还债务支付的现金---23,614,136.5
  分配股利、利润或偿付利息支付的现金263,244,250.24263,214,350.2429,25047,385,071.79
  支付其他与筹资活动有关的现金16,236,996.7916,026,786.7915,606,366.79264,046,006.56
  筹资活动现金流出小计279,481,247.03279,241,137.0315,635,616.79335,045,214.85
  筹资活动产生的现金流量净额-279,481,247.03-279,241,137.03-15,635,616.79-313,168,468.86
四、汇率变动对现金及现金等价物的影响-639,623.25-176,613.02-37,577.57506,232.79
五、现金及现金等价物净增加额-194,342,123.93-145,240,728.59-141,220,514.03-535,833,311.48
  加:期初现金及现金等价物余额378,206,563.5378,206,563.5378,206,563.5914,039,874.98
  期末现金及现金等价物余额183,864,439.57232,965,834.91236,986,049.47378,206,563.5
补充资料:
  净利润-6,625,836.4-26,564,716.49
  资产减值准备--3,131,301.02-86,919,196.43
  固定资产和投资性房地产折旧-30,937,760.66-56,160,238.89
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-30,937,760.66-56,160,238.89
  无形资产摊销-460,807.74-889,321.02
  长期待摊费用摊销-526,982.04-14,509,915.12
  处置固定资产、无形资产和其他长期资产的损失-74,004.12--1,792,048.58
  固定资产报废损失-0-83,605.84
  公允价值变动损失-1,149,546.14--1,736,551.64
  财务费用--1,921,746.21-672,294.91
  投资损失--49,346,432.75--133,703,042.86
  递延所得税--1,943,211.3-4,107,909.38
  其中:递延所得税资产减少--3,189,991.68--6,723,751.63
    递延所得税负债增加-1,246,780.38-10,831,661.01
  存货的减少--7,415,786.91-84,756,216.39
  经营性应收项目的减少-45,908,360.12-411,715,426.33
  经营性应付项目的增加--126,021,272.41--644,136,195.52
  其他-15,074,994.7-4,007,552.47
  债务转为资本-0--
  一年内到期的可转换公司债券-0--
  融资租入固定资产-0--
  现金的期末余额-232,965,834.91-378,206,563.5
  减:现金的期初余额-378,206,563.5-914,039,874.98
  加:现金等价物的期末余额-0--
  减:现金等价物的期初余额-0--
  现金及现金等价物的净增加额--145,240,728.59--535,833,311.48
公告日期2025-10-312025-08-282025-04-302025-04-25
审计意见(境内)标准无保留意见
TOP↑